Closed-loop control of tumor growth by means of anti-angiogenic administration

  • Received: 21 February 2017 Accepted: 20 December 2017 Published: 01 August 2018
  • MSC : Primary: 92B05, 93C10, 93C55, 93B52, 93B07

  • A tumor growth model accounting for angiogenic stimulation and inhibition is here considered, and a closed-loop control law is presented with the aim of tumor volume reduction by means of anti-angiogenic administration. To this end the output-feedback linearization theory is exploited, with the feedback designed on the basis of a state observer for nonlinear systems. Measurements are supposed to be acquired at discrete sampling times, and a novel theoretical development in the area of time-delay systems is applied in order to derive a continuous-time observer in spite of the presence of sampled measurements. The overall control scheme allows to set independently the control and the observer parameters thanks to the structural properties of the tumor growth model. Simulations are carried out in order to mimic a real experimental framework on mice. These results seem extremely promising: they provide very good performances according to the measurements sampling interval suggested by the experimental literature, and show a noticeable level of robustness against the observer initial estimate, as well as against the uncertainties affecting the model parameters.

    Citation: Filippo Cacace, Valerio Cusimano, Alfredo Germani, Pasquale Palumbo, Federico Papa. Closed-loop control of tumor growth by means of anti-angiogenic administration[J]. Mathematical Biosciences and Engineering, 2018, 15(4): 827-839. doi: 10.3934/mbe.2018037

    Related Papers:

  • A tumor growth model accounting for angiogenic stimulation and inhibition is here considered, and a closed-loop control law is presented with the aim of tumor volume reduction by means of anti-angiogenic administration. To this end the output-feedback linearization theory is exploited, with the feedback designed on the basis of a state observer for nonlinear systems. Measurements are supposed to be acquired at discrete sampling times, and a novel theoretical development in the area of time-delay systems is applied in order to derive a continuous-time observer in spite of the presence of sampled measurements. The overall control scheme allows to set independently the control and the observer parameters thanks to the structural properties of the tumor growth model. Simulations are carried out in order to mimic a real experimental framework on mice. These results seem extremely promising: they provide very good performances according to the measurements sampling interval suggested by the experimental literature, and show a noticeable level of robustness against the observer initial estimate, as well as against the uncertainties affecting the model parameters.
    加载中
    [1] [ W. Arap,R. Pasqualini,E. Ruoslahti, Chemotherapy targeted to tumor vasculature, Current Opinion in Oncology, 10 (1998): 560-565.
    [2] [ F. Cacace, A. Germani and C. Manes, State estimation and control of nonlinear systems with large and variable measurement delays, Recent Results on Nonlinear Delay Control Systems, Springer International Publishing, 4 (2016), 95–112.
    [3] [ F. Cacace,A. Germani,C. Manes, A chain observer for nonlinear systems with multiple time-varying measurement delays, SIAM Journal Control and Optimization, 52 (2014): 1862-1885.
    [4] [ G. Ciccarella,M. Dalla Mora,A. Germani, A Luemberger-like observer for nonlinear systems, International Journal of Control, 57 (1993): 537-556.
    [5] [ V. Cusimano, P. Palumbo and F. Papa, Closed-loop control of tumor growth by means of antiangiogenic administration, 54th IEEE Conference on Decision and Control (CDC), Osaka, Japan, 2015,7789–7794.
    [6] [ M. Dalla Mora,A. Germani,C. Manes, Design of state observers from a drift-observability property, IEEE Transactions on Automatic Control, 45 (2000): 1536-1540.
    [7] [ J. Denekamp, Vascular attack as a therapeutic strategy for cancer, Cancer and Metastasis Reviews, 9 (1990): 267-282.
    [8] [ A. D'Onofrio,A. Gandolfi, Tumour eradication by antiangiogenic therapy: Analysis and extensions of the model by hahnfeldt et al. (1999), Mathematical Biosciences, 191 (2004): 159-184.
    [9] [ A. D'Onofrio,A. Gandolfi, Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular "Pruning", Journal of Theoretical Biology, 264 (2010): 253-265.
    [10] [ A. D'Onofrio,U. Ledzewicz,H. Maurer,H. Schattler, On optimal delivery of combination therapy for tumors, Mathematical Biosciences, 222 (2009): 13-26.
    [11] [ A. Ergun,K. Camphausen,L. M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bulletin of Mathematical Biology, 65 (2003): 407-424.
    [12] [ J. Folkman, P. Hahnfeldt and L. Hlatky, The logic of anti-angiogenic gene therapy, The Development of Gene Therapy, Cold Sping Harbor, New York, 1998, 1–17.
    [13] [ J. Folkman, Anti-angiogenesis: New concept for therapy of solid tumors, Annals of Surgery, 175 (1972): 409-416.
    [14] [ P. Hahnfeldt,D. Panigrahy,J. Folkman,L. Hlatky, Tumor Development under Angiogenic Signaling: A Dynamical Theory of Tumor Growth, Treatment Response, and Postvascular Dormancy, Cancer Research, 59 (1999): 4770-4775.
    [15] [ A. Isidori, Nonlinear Control Systems, Springer, London, 1995.
    [16] [ R. S. Kerbel, Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents, BioEssays, 13 (1991): 31-36.
    [17] [ R. S. Kerbel, A cancer therapy resistant to resistance, Nature, 390 (1997): 335-336.
    [18] [ R. S. Kerbel,G. Klement,K. I. Pritchard,B. Kamen, Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic, Annals of Oncology, 13 (2002): 12-15.
    [19] [ K. S. Kerbel,B. A. Kamen, The anti-angiogenic basis of metronomic chemotherapy, Nature Reviews Cancer, 4 (2004): 423-436.
    [20] [ M. Klagsbrun,S. Soker, VEiGF/VPF: The angiogenesis factor found?, Current Biology, 3 (1993): 699-702.
    [21] [ J. Klamka,H. Maurer,A. Swierniak, Local controllability and optimal control for a model of combined anticancer therapy with control delays, Mathematical Biosciences and Engineering, 14 (2017): 195-216.
    [22] [ L. Kovács,A. Szeles,J. Sápi,D. A. Drexler,I. Rudas,I. Harmati,Z. Sápi, Model-based angiogenic inhibition of tumor growth using modern robust control method, Computer Methods and Programs in Biomedicine, 114 (2014): e98-e110.
    [23] [ U. Ledzewicz,H. Schattler, Anti-angiogenic therapy incancer treatment as an optimal control problem, SIAM Journal on Control and Optimization, 46 (2007): 1052-1079.
    [24] [ U. Ledzewicz,J. Marriott,H. Maurer,H. Schattler, Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment, Mathematical Medicine and Biology, 27 (2010): 157-179.
    [25] [ Yu. Mikheev,V. Sobolev,E. Fridman, Asymptotic analysis of digital control systems, Automation and Remote Control, 49 (1988): 1175-1180.
    [26] [ J. Sápi,D. A. Drexler,I. Harmati,Z. Sápi,L. Kovács, Qualitative analysis of tumor growth model under antiangiogenic therapy -choosing the effective operating point and design parameters for controller design, Optimal Control Applications and Methods, 37 (2016): 848-866.

    © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
  • Reader Comments
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(669) PDF downloads(467) Cited by(9)

Article outline

Figures and Tables

Figures(2)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog